What diseases is brigatinib suitable for?

Brigatinib (Brigatinib) is a highly effective targeted drug mainly used to treat specific cancer types.

1. Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Brigatinib is mainly used to treat patients with ALK positive locally advanced or metastatic non-small cell lung cancer. ALKpositiveNSCLCaccounts for about 3-5% of all NSCLC cases. Such patients usually have specific gene mutations that allow cancer cells to proliferate rapidly. As a second-generation ALK inhibitor, brigatinib can effectively target this gene mutation, thereby inhibiting the growth and spread of cancer cells.

2. Patients with disease progression or intolerance after treatment with crizotinib (Crizotinib)

Brigatinib is an important treatment option for patients who have previously received crizotinib but have progressed or are intolerant to the drug. Clinical studies have shown that brigatinib has shown significant efficacy in such patients, especially in patients with brain metastases. After treatment with brigatinib, the progression-free survival time of patients has been significantly prolonged.

3. Patients resistant to Osimertinib (Osimertinib)

In addition to the two main indications mentioned above, brigatinib also shows potential in treating osimertinib-resistant patients. Osimertinib is a third-generation EGFR inhibitor used to treat EGFR-mutated NSCLC. However, some patients may develop resistance to osimertinib. Brigatinib works through its unique dual inhibitory mechanism (simultaneously inhibiting ALK andEGFR), providing new treatment strategies for these patients.

4. Other potential applications

In addition, brigatinib is also exploring the therapeutic effect of other cancer types, such asROS1rearrangedNSCLC, etc. Its broad kinase inhibitory activity makes brigatinib an effective drug for the treatment of various cancers in the future.

References:

https://www.alunbrig.com/